Drug Trial Radar · NCT06982729
Study of YK012 in Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Nov 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 8, 2025
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Excyte Biopharma LtdIndustry
- Sponsor type
- Industry
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).
Conditions
- Primary Membranous Nephropathy
Interventions
YK012Drug
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ia: Dose-limiting Toxicity(DLT)Time frame: up to 28 days after the first dose
- Ia: Adverse Event (AE)Time frame: From the first induction to the end of the trial at 53 weeks
- Ia: Severe Adverse EventTime frame: From the first induction to the end of the trial at 53 weeks
- Ib: Proportion of participants achieving overall responseTime frame: From enrollment to the end of the trial at 76 weeks (if applicable)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.